The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population

Gynecological Endocrinology

Volumn 22, Issue 2, 2006, Pages 87-91

  Tsujino, Taro ^a   Ohara, Noriyuki ^a   Yoshida, Shigeki ^a   Kennedy, Stephen ^b   Takemura, Naoya ^a   Deguchi, Masashi ^a   Maruo, Takeshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CYP17 MspA1; Gene polymorphism; Leiomyoma; Polymerase chain reaction; Restriction fragment length polymorphism

Indexed keywords

CYTOCHROME P450 17;

ALLELE; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION STRUCTURE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; UTERUS MYOMA;

ALLELES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; LEIOMYOMA; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STEROID 17-ALPHA-HYDROXYLASE; UTERINE NEOPLASMS;

EID: 33645796913     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500476222     Document Type: Article

References (32)

1. Otubu JA, Buttram VC, Besch NF, Besch PK. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982;143:130-133.
2. Pasqualini JR, Cornier E, Grenier J, Vella C, Schatz B, Netter A. Effect of decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium. Fertil Steril 1990;53:1012-1017.
3. Sumitani H, Shozu M, Segawa T, Murakami K, Yang HJ, Shimada K, Inoue M. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology 2000;141:3852-3861.
4. Benassayag C, Leroy MJ, Rigourd V, Robert B, Honore JC, Mignot TM, Vacher-Lavenu MC, Chapron C, Ferre F. Estrogen receptors (ERα/ERβ) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol Endocrinol Metab 1999;276:E1112-E1118.
5. Kovács KA, Oszter A, Göcze PM, Környei JL, Szabó I. Comparative analysis of cyclin D1 and oestrogen receptor (α and β) levels in human leiomyoma and adjacent myometrium. Mol Hum Reprod 2001;7:1085-1091.
6. Weel AE, Uitterlinden AG, Westendorp IC, Burger H, Schuit SC, Hofman A, Helmerhorst TJ, van Leeuwen JP, Pols HA. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 1999;84:3146-3150.
7. Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, Tsukamoto K, Hasegawa G, Nakamura N, Honjo H. Oestrogen receptor-α gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum Reprod 2001;16:51-55.
8. Massart F, Becherini L, Gennari L, Facchini V, Genazzani AR, Brandi ML. Genotype distribution of estrogen receptor-α gene polymorphisms in Italian women with surgical uterine leiomyomas. Fertil Steril 2001;75:567-570.
9. Hsieh YY, Chang CC, Tsai FJ, Tsai HD, Yeh LS, Lin CC, Tsai CH. Estrogen receptor thymine-adenine dinucleotide repeat polymorphism is associated with susceptibility to leiomyoma. Fertil Steril 2003;79:96-99.
10. Zuber MX, Simpson ER, Waterman MR. Expression of bovine 17α-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science 1986;234:1258-1261.
11. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17α-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987;6:439-448.
12. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-1876.
13. Kristensen VN, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59:2825-2828.
14. Huang C-S, Chern H-D, Chang K-J, Cheng C-W, Hsu S-M, Shen C-Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-4875.
15. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001;61:785-789.
16. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, de Vivo I. Apolymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001,61:3955-3960.
17. Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001;92:683-686.
18. Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghotu C, Jackson A, Ukoli F, Adams-Campbell L, Isaacs W, Dunston GM. CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001;10:943-947.
19. Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z, Ostrander EA. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11:243-247.
20. Garner EIO, Stokes EE, Berkowitz RS, Mok SC, Cramer DW. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002;62:3058-3062.
21. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytchrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-587.
22. Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 2003;5:R45-R51.
23. Wu AH, Seow A, Arakawa K, Van den Berg D, Lee H-P, Yu MC. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 2003;104:450-457.
24. Ntais C, Polycarpou A, Ioannidis JPA. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:120-126.
25. Spurdle AB, Chen X, Abbazadegan M, Martin N, Khoo SK, Hurst T, Ward B, Webb PM, Chenevix-Trench G. CYP17 promoter polymorphism and ovarian cancer risk. Int J Cancer 2000;86:436-439.
26. Goodman MT, McDuffie K, Guo C, Terada K, Donlon TA. CYP17 genotype and ovarian cancer: a null case-control study. Cancer Epidemiol Biomarkers Prev 2001;10:563-564.
27. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 2000;36:2375-2379.
28. Kado N, Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Tsukamoto K, Hasegawa G, Nakamura N, Yoshikawa T, Honjo H. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum Reprod 2002;17:897-902.
29. Fujimoto J, Hirose R, Sakaguchi H, Tamaya T. Expression of size-polymorphic androgen receptor gene in uterine leiomyoma according to the number of cytosine, adenine, and guanine repeats in androgen receptor alleles. Tumour Biol 2000;21:33-37.
30. Hashimoto K, Azuma C, Kamiura S, Koyama M, Nobunaga T, Tokugawa Y, Kimura T, Kubota Y, Sawai K, Saji F. Maintenance of imprinting of the insulin-like growth factor II gene (IGF2) and the small nuclear ribonucleoprotein polypeptide N gene (SNRPN) in the human uterus and leiomyoma. Gynecol Obstet Invest 1996;41:50-54.
31. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 2000;89:325-328.
32. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A. Polymorphic catechol-O- methyltranferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:635-640.